<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2357">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366765</url>
  </required_header>
  <id_info>
    <org_study_id>UHospital Switz</org_study_id>
    <nct_id>NCT04366765</nct_id>
  </id_info>
  <brief_title>COVID-19 Survival - The COVIVA Study</brief_title>
  <acronym>COVIVA</acronym>
  <official_title>Coronavirus Disease 19 Survival - The COVIVA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 pandemic poses a major and imminent challenge for health care systems regarding&#xD;
      patient triage and allocation of limited resources worldwide. The involved pathogenetic&#xD;
      mechanisms as well as the clinical value of established and emerging biomarkers for early&#xD;
      risk prediction are largely unknown.&#xD;
&#xD;
      To fill these gaps in knowledge, investigators designed the prospective, interdisciplinary,&#xD;
      observational, case-control &quot;COronaVIrus surviVAl (COVIVA)&quot; study platform, aiming to deliver&#xD;
      an open-source platform to i) perform extensive clinical and biomarker phenotyping in&#xD;
      COVID-19 suspects presenting to the emergency department (ED) as well as admitted to the&#xD;
      intensive care unit, ii) compare clinical and biomarker profiles of COVID-19 patients with a&#xD;
      control group, iii) derive and validate personalized risk prediction models for early&#xD;
      clinical decision support, and iv) explore pathophysiological mechanisms including but not&#xD;
      limited to inflammatory, immunological and cardiovascular pathways.&#xD;
&#xD;
      Blood samples (serum) are routinely collected for bio banking both in cases and controls.&#xD;
      Patients are followed 30 days after discharge. Personalized risk prediction models will be&#xD;
      derived and validated based on advanced statistical models including machine-based learning&#xD;
      incorporating a variety of clinical parameters and biomarker signatures (including digitally&#xD;
      stored in-hospital data, e.g. imaging, ECG, ventilation parameters). Close cooperation with&#xD;
      multiple other national and international COVID-19 cohorts is endorsed.&#xD;
&#xD;
      The personalized risk prediction models from the COVIVA study will support clinicians in the&#xD;
      most challenging process of limited resource allocation in a timely fashion. In addition,&#xD;
      pathophysiological mechanisms and differences in mild and severe variants of COVID-19 as well&#xD;
      as in the control group can be extensively studied in a multidisciplinary approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The current COVID-19 pandemic poses a major and imminent challenge for health&#xD;
      care systems regarding patient triage and allocation of limited resources worldwide, but also&#xD;
      in Switzerland. Data from severly affected countries impressively demonstrate that COVID-19&#xD;
      fatality rates rapidly increase in times of overloaded health care services. Cardiovascular&#xD;
      comorbidity seems to be associated with impaired outcome, e.g. with admission to intensive&#xD;
      care unit (ICU) or death. However, a direct causal relation is questionable and&#xD;
      pathophysiological mechanisms of the cardiovascular involvement such as the&#xD;
      renin-angiotensin-aldosterone system are poorly understood. The clinical value of established&#xD;
      and emerging biomarkers is largely unknown. Accordingly, early and reliable personalized risk&#xD;
      prediction represents a major unmet clinical need, as it may allow evidence-based clinical&#xD;
      decision aid for most effective resource allocation in the common fight against the COVID-19&#xD;
      pandemic.&#xD;
&#xD;
      Aims: To fill these gaps in knowledge, investigators designed the &quot;COronaVIrus surviVAl&#xD;
      (COVIVA)&quot; study. With this study, investigators aim to deliver an open-source platform to i)&#xD;
      perform extensive clinical and biomarker phenotyping in COVID-19 suspects presenting to the&#xD;
      emergency department (ED) and in COVID-19 patients with subsequent ICU admission, ii) compare&#xD;
      clinical and biomarker profiles of COVID-19 patients with a control group, iii) derive and&#xD;
      validate personalized risk prediction models for early clinical decision support, and iv)&#xD;
      explore pathophysiological mechanisms including inflammatory and cardiovascular pathways.&#xD;
&#xD;
      Methodology: The COVIVA study is an ongoing, prospective, interdisciplinary, observational,&#xD;
      case-control study with active enrolment of consecutive patients with clinical suspicion of&#xD;
      COVID-19 triaged to the Emergency Department (ED) of the University Hospital in Basel,&#xD;
      Switzerland. Patients with a positive nasopharyngeal swab test for severe acute respiratory&#xD;
      syndrome (SARS)-CoV-2 will serve as cases while the remainders will serve as controls.&#xD;
      Detailed clinical patient's phenotyping (e.g. comorbidities, medications, symptoms, vitals,&#xD;
      ECG and imaging data), extended laboratory analyses and blood sampling for bio banking are&#xD;
      performed once in all patients (cases and control) at time of ED presentation and serially&#xD;
      thereafter in the subset of COVID-19 patients with subsequent need for ICU admission. Primary&#xD;
      outcome measure is in-hospital mortality; secondary outcome measures include the need for ICU&#xD;
      admission, invasive mechanical ventilation, hemodynamic support, 30-day post-discharge&#xD;
      mortality, length of hospital and ICU stay, resource use and quality of life 30 days after&#xD;
      discharge and its composites. Personalized risk prediction models will be derived and&#xD;
      validated based on advanced statistical models including machine-based learning incorporating&#xD;
      a variety of clinical parameters and biomarker signatures (including digitally stored&#xD;
      in-hospital data, e.g. imaging, ECG, ventilation parameters). Close cooperation with multiple&#xD;
      other national and international COVID-19 cohorts is endorsed.&#xD;
&#xD;
      Potential significance: The personalized risk prediction models from the COVIVA study will&#xD;
      support clinicians in the most challenging process of limited resource allocation in a timely&#xD;
      fashion. In addition, pathophysiological mechanisms and differences in mild and severe&#xD;
      variants of COVID-19 as well as in the control group can be extensively studied in a&#xD;
      multidisciplinary approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>short-term prognosis</measure>
    <time_frame>at 30 days</time_frame>
    <description>incidence of death during index hospital stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Admission to the intensive care unit (ICU)</measure>
    <time_frame>at 30 days</time_frame>
    <description>Incidence of subsequent ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive ventilation (Intubation)</measure>
    <time_frame>at 30 days</time_frame>
    <description>Incidence of subsequent intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for extracorporal membrane oxygenation (ECMO)</measure>
    <time_frame>at 30 days</time_frame>
    <description>Incidence of subsequent ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic support</measure>
    <time_frame>at 30 days</time_frame>
    <description>Incidence of subsequent need for hemodynamic support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>at 30 days</time_frame>
    <description>Number of days (overnight-stays) spent on the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory distress Syndrome (ARDS)</measure>
    <time_frame>at 30 days</time_frame>
    <description>Incidence o ARDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury</measure>
    <time_frame>at 30 days</time_frame>
    <description>Incidence of myocardial injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-segment elevation myocardial infarction</measure>
    <time_frame>at 30 days</time_frame>
    <description>Incidence of myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital resource use</measure>
    <time_frame>at 30 days</time_frame>
    <description>Types and numbers of resources used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D questionnaire</measure>
    <time_frame>at 30 days</time_frame>
    <description>Quality of life assessed using the EQ-5D questionnaire resulting in an indexed score ranging from 0 to 1 with higher numbers indicating higher quality of life.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>COVID-19 suspects</arm_group_label>
    <description>Patients presenting with suspected COVID-19 to the emergency department of the University Hospital Basel.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Serum sampling&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with clinical suspicion of COVID-19 or confirmed SARS-CoV2 infection triaged&#xD;
        to the Emergency Department (ED) of the University Hospital Basel, Switzerland, are&#xD;
        potentially eligible for enrolment in this study. An upstream pre-triage located outside&#xD;
        the ED (in a nearby church) routinely performs clinical risk assessment in all patients&#xD;
        with clinical suspicion of SARS-CoV-2 infection irrespective of symptoms severity and, if&#xD;
        clinically indicated, nasopharyngeal swab testing. While patients with mild symptoms and in&#xD;
        good clinical condition are assigned towards outpatient management, patients in poorer&#xD;
        clinical conditions and higher likelihood of need for in-patient management are assigned to&#xD;
        the ED, where they will be screened for potential COVIVA inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically suspected or confirmed SARS-CoV-2 infection triaged to the ED&#xD;
&#xD;
          -  SARS-CoV-2 swab test performed (result may be pending at time of study enrolment)&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  Patient or legally authorized representative is willing to sign local General consent&#xD;
             form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient or legally authorized representative is unable or unwilling to participate in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Twerenbold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology and Cardiodiovascular Research Institute Basel (CRIB)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriela Kuster Pfister, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphael Twerenbold, MD</last_name>
    <phone>0041 61 328 72 16</phone>
    <email>raphael.twerenbold@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriela Kuster Pfister, MD</last_name>
    <phone>0041 61 328 72 16</phone>
    <email>gabriela.kuster@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphael Twerenbold, MD</last_name>
      <phone>0041 61 328 72 16</phone>
      <email>raphael.twerenbold@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Gabriela Kuster Pfister, MD</last_name>
      <phone>0041 61 328 72 16</phone>
      <email>gabriela.kuster@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Roland Bingisser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Nickel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Pargger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Siegemund, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Rentsch-Savoca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefano Bassetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Tschudin-Sutter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mirjam Christ Crain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Mueller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Osswald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>precision medicine</keyword>
  <keyword>risk prediction</keyword>
  <keyword>pathomechanisms</keyword>
  <keyword>renin-angiotensin-aldosterone system (RAAS)</keyword>
  <keyword>biomarkers</keyword>
  <keyword>biobank</keyword>
  <keyword>serum</keyword>
  <keyword>resource allocation</keyword>
  <keyword>artificial intelligence</keyword>
  <keyword>big data</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

